Evolved Therapeutics develops functional antibodies using a novel discovery platform that integrates high-throughput screening with advanced protein engineering. The approach accelerates the identification of therapeutic candidates that modulate disease-relevant targets, reducing development timelines compared with traditional antibody pipelines.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody discovery pipelines rely heavily on binding affinity screens, which often yield candidates that lack the desired functional activity, leading to long development timelines and high attrition rates for therapeutics targeting complex disease pathways.
Solution
Evolved Therapeutics employs a discovery platform that combines high‑throughput functional screening with advanced protein engineering to identify antibodies based on their biological activity rather than just binding strength. The integrated workflow accelerates candidate selection by rapidly pinpointing molecules that modulate disease‑relevant targets, shortening preclinical timelines. By focusing on functional efficacy early in the pipeline, the company aims to generate biologics with higher therapeutic potential for unmet medical needs.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to discover or license functional antibody therapeutics for indications with unmet clinical needs.
Features
- High‑throughput functional assays that assess target modulation directly, not just binding
- Iterative protein engineering cycles to optimize activity, specificity, and developability
- Integrated data analytics pipeline to prioritize candidates based on functional readouts
- Scalable platform adaptable to a wide range of disease targets and therapeutic modalities
- Rapid lead identification that reduces overall discovery timelines compared with conventional methods